Stockscreener 앱 받기
505.75
1.18%
5.89
시간 외 거래:
505.75
전일 마감가:
$499.86
열려 있는:
$500.38
하루 거래량:
486.96K
Relative Volume:
1.56
시가총액:
$11.66B
수익:
$1.13B
순이익/손실:
$-309.44M
주가수익비율:
-39.51
EPS:
-12.8001
순현금흐름:
$-275.41M
1주 성능:
+6.64%
1개월 성능:
-3.16%
6개월 성능:
-7.10%
1년 성능:
+78.89%
1일 변동 폭
$485.56
$511.28
1주일 범위
$469.07
$511.28
52주 변동 폭
$276.67
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
505.75 | 11.66B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals Stockweekly review and NASH sector context - AD HOC NEWS
Madrigal Pharmaceuticals Inc - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal (MDGL) director Richard Levy receives new RSU and stock option grants - Stock Titan
Madrigal Pharmaceuticals (MDGL) director granted RSUs and stock options - Stock Titan
Madrigal (MDGL) director James Daly granted RSUs and 766-share option - Stock Titan
Madrigal (MDGL) director receives stock grants and 681-share option award - Stock Titan
Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards - Stock Titan
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes - Investing.com Nigeria
Madrigal (NASDAQ: MDGL) updates equity, ESPP and deferred pay plans - Stock Titan
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Cooperating With NICE On MASH Drug After Provisional English Funding Rejection - Citeline News & Insights
Price-Driven Insight from (MDGL) for Rule-Based Strategy - Stock Traders Daily
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
MDGL Maintained by B of A Securities -- Price Target Lowered to $542 - GuruFocus
BofA cuts Madrigal Pharmaceuticals price target on competition concerns By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals launches 'MASH Across America' with giant inflatable liver in Philly - PharmaLive
MDGL: Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained growth - TradingView
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
MDGL Q1 2026 Earnings: Narrower Loss Surprises MarketsEarnings Yield Spread - lwvtexas.org
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event - MyChesCo
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential - DirectorsTalk Interviews
Goldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Fiera Capital Corp Acquires 41,656 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Return on invested capital % of Madrigal Pharmaceuticals, Inc. – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. News — XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1 - TradingView
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com
(MDGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Legal & General Group Plc Sells 6,440 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress - Insider Monkey
Madrigal Highlights Rezdiffra Data as MASH Market Expands - MyChesCo
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - The Manila Times
12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Geode Capital Management LLC Has $263.11 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals targets liver disease with Rezdiffra, eyeing strong growth despite competition risks. - Pluang
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits - Quiver Quantitative
Insider Sell: David Soergel Sells Shares of Madrigal Pharmaceuti - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):